Advertisement


Toni K. Choueiri, MD, on RCC: Results From the CABOSUN Trial

2017 ESMO Congress

Advertisement

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses updated overall survival results on cabozantinib vs sunitinib as initial targeted treatment for patients with metastatic renal cell carcinoma (Abstract LBA38).



Related Videos

Breast Cancer

Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: Expert Perspective on CDK4 Inhibitors

Sibylle Loibl, MD, PhD, of the German Breast Group, summarizes a session she chaired in which the rationale to target CDK4, data on efficacy of the inhibitors, and triple combinati...

Pancreatic Cancer

David A. Tuveson, MD, PhD, on Progress in Pancreatic Cancer: Expert Perspective

David A. Tuveson, MD, PhD, of Cold Spring Harbor Laboratory, discusses the most lethal of cancers. Although treatments are improving, the challenges are great, including early dete...

Skin Cancer

Jeffrey S. Weber, MD, PhD, on Melanoma: Results of the CheckMate 238 Trial

Jeffrey S. Weber, MD, PhD, of New York University’s Langone Medical Center, discusses study results on adjuvant therapy with nivolumab vs ipilimumab after complete resection of sta...

Head and Neck Cancer

Robert I. Haddad, MD, on Head and Neck Cancer: Results of the CheckMate 141 Trial

Robert I. Haddad, MD, of Dana-Farber Cancer Institute, discusses phase III study results on treatment beyond disease progression with nivolumab in patients with recurrent or metast...

Kidney Cancer

Bernard J. Escudier, MD, on RCC: Results From the CheckMate 214 Trial

Bernard J. Escudier, MD, of Gustave Roussy, discusses efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma,...

Advertisement

Advertisement



Advertisement